In Type 2 Diabetes, SGLT2 Inhibitors Tied to Lower CV Risk R
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Short-term use of sodium glucose cotransporter 2 (SGLT2) inhibitors is associated with reduced risk for major cardiovascular events in patients with type 2 diabetes, compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, according to a retrospective study in The BMJ.

Using Canadian and U.K. databases, researchers matched over 200,000 new users of SGLT2 inhibitors with new users of DPP-4 inhibitors.

During a mean follow-up of almost 1 year, major adverse cardiovascular events (myocardial infarction, ischemic stroke, or cardiovascular death) occurred significantly less often in SGLT2-inhibitor users (11.4 vs. 16.5 per 1000 person-years for DPP-4 inhibitors). The risk reduction was strongest for cardiovascular death. The SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin all showed similar cardiovascular risk reductions.

The authors conclude: "These findings suggest that SGLT2 inhibitors offer cardioprotective benefits among people with type 2 diabetes in a real world setting, although additional studies are needed to determine if these benefits persist long term."

Source: https://www.bmj.com/content/370/bmj.m3342
Like
Comment
Share